retatrutide and bpc 157 together (GLP-3) – Y&P Labs retatrutide and bpc 157 retatrutide

They are extensively used in clinical settings in Russia and Eastern Europe, where several hold registered pharmaceutical status

Importantly, BPC-157 demonstrates no interference with normal bone remodeling processes, maintaining the balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption necessary for proper structural regeneration

Dry powder = very stable

All other drugs with a positive effect in neurological symptoms in a preclinical trial in SCA3 rodent models (and which have not been tested in SCA3 patients) are not used in the clinic for other disorders

Others, like GHK-CU, melanotan and retatrutide are not approved for human use as a default

Regular follow-up appointments allow us to track your progress and make any necessary adjustments to your treatment plan